S. Pol

1.0k total citations
54 papers, 660 citations indexed

About

S. Pol is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, S. Pol has authored 54 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hepatology, 34 papers in Epidemiology and 10 papers in Rheumatology. Recurrent topics in S. Pol's work include Hepatitis C virus research (38 papers), Liver Disease Diagnosis and Treatment (23 papers) and Hepatitis B Virus Studies (18 papers). S. Pol is often cited by papers focused on Hepatitis C virus research (38 papers), Liver Disease Diagnosis and Treatment (23 papers) and Hepatitis B Virus Studies (18 papers). S. Pol collaborates with scholars based in France, United States and Switzerland. S. Pol's co-authors include Henri Kreis, Marie‐Laure Chaix, Paul Landais, Christine Le Bihan-Benjamin, Marie‐France Mamzer, C. Legendre, Valérie Garrigue, C Bréchot, F Carnot and Claude Degott and has published in prestigious journals such as The Lancet, Hepatology and Clinical Infectious Diseases.

In The Last Decade

S. Pol

49 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Pol France 11 571 474 124 99 52 54 660
C. Fretz France 13 766 1.3× 713 1.5× 140 1.1× 119 1.2× 29 0.6× 20 935
C. Cornù Belgium 13 633 1.1× 618 1.3× 60 0.5× 181 1.8× 53 1.0× 38 858
P. Wantzin Denmark 13 537 0.9× 513 1.1× 38 0.3× 98 1.0× 32 0.6× 26 671
Raymond T. Chung United States 9 814 1.4× 725 1.5× 69 0.6× 367 3.7× 61 1.2× 12 1.0k
H. Benalia France 4 382 0.7× 367 0.8× 129 1.0× 86 0.9× 16 0.3× 10 514
Roberto José de Carvalho‐Filho Brazil 16 933 1.6× 909 1.9× 19 0.2× 92 0.9× 67 1.3× 59 1.1k
Jeanne Serpaggi France 9 738 1.3× 697 1.5× 18 0.1× 73 0.7× 10 0.2× 9 799
Sergio Rojter United States 12 630 1.1× 586 1.2× 16 0.1× 94 0.9× 26 0.5× 22 744
M. Abradelo Spain 17 511 0.9× 365 0.8× 176 1.4× 91 0.9× 7 0.1× 41 739
Sylvie Radenne France 15 795 1.4× 657 1.4× 107 0.9× 49 0.5× 12 0.2× 41 981

Countries citing papers authored by S. Pol

Since Specialization
Citations

This map shows the geographic impact of S. Pol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Pol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Pol more than expected).

Fields of papers citing papers by S. Pol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Pol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Pol. The network helps show where S. Pol may publish in the future.

Co-authorship network of co-authors of S. Pol

This figure shows the co-authorship network connecting the top 25 collaborators of S. Pol. A scholar is included among the top collaborators of S. Pol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Pol. S. Pol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pol, S. & Anand Prakash. (2023). Engagement in Structured Extracurricular Activities: A Preventive Measure for Technology Addiction in Adolescents. Science Insights Education Frontiers. 16(2). 2537–2563.
2.
Obach, Dorothée, Sylvie Deuffic‐Burban, Gamal Esmat, et al.. (2013). 885 IMMEDIATE vs. DELAYED TREATMENT IN GENOTYPE 4-HCV INFECTED PATIENTS IN A LIMITED RESOURCES COUNTRY: A COST-EFFECTIVENESS ANALYSIS IN EGYPT (ANRS 12215). Journal of Hepatology. 58. S364–S364. 2 indexed citations
3.
Saadoun, David, Vincent Thibault, M. Longuet, et al.. (2013). Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases. 73(5). 831–837. 57 indexed citations
4.
Bronowicki, J.‐P., Christophe Hézode, Leif Bengtsson, et al.. (2012). 1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL. Journal of Hepatology. 56. S430–S431. 34 indexed citations
5.
Sulkowski, Mark, M. Rodríguez‐Torres, E. Läwitz, et al.. (2012). 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS. Journal of Hepatology. 56. S560–S560. 37 indexed citations
6.
Fontaine, H., Cyrille Chazallon, Maryline Bourgine, et al.. (2011). 1367 RELAPSE AFTER ANALOGUES TREATMENT DISCONTINUATION IS NOT PREVENTED BY DNA VACCINATION IN CHRONIC HEPATITIS B (ANRS HB 02 VAC-ADN). Journal of Hepatology. 54. S542–S542. 3 indexed citations
7.
8.
9.
Halfon, P., Fabrice Carrat, Pierre Bédossa, et al.. (2008). 791 IMPACT OF ANTIVIRAL TREATMENT ON NON INVASIVE PREDICTORS OF LIVER FIBROSIS IN HIV-HCV CO-INFECTED PATIENTS: THE FIBROVIC 2 STUDY-ANRS HC02. Journal of Hepatology. 48. S295–S295. 1 indexed citations
10.
Pol, S., et al.. (2008). L’hépatite B occulte. Virologie. 12(2). 87–94. 3 indexed citations
11.
Marcellin, Patrick, J.F. Cadranel, Thierry Fontanges, et al.. (2007). [509] WHICH PATIENTS WITH CHRONIC HEPATITIS B ARE TREATED AND HOW: A CROSS-SECTIONAL STUDY IN FRANCE ON 1790 PATIENTS. Journal of Hepatology. 46. S194–S194. 1 indexed citations
12.
Halfon, Philippe, S. Pol, Marc Bourlière, Jérôme Courcambeck, & P. Cacoub. (2003). Résistance aux analogues de nucléosides dans le traitement de l’hépatite chronique B. La Revue de Médecine Interne. 24(12). 786–793.
13.
Roudot‐Thoraval, Françoise, Armand Abergel, François‐André Allaert, et al.. (2001). [Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences].. PubMed. 25(12). 1061–6. 9 indexed citations
14.
Pol, S.. (2000). Treatment of hepatitis C virus infection in dialysis patients. Nephrology Dialysis Transplantation. 15(90008). 46–48. 6 indexed citations
15.
Pol, S., Lawrence Serfaty, F Carnot, et al.. (2000). Reversibility of hepatitis C virus-related (HCV) cirrhosis. Journal of Hepatology. 32. 101–101. 5 indexed citations
16.
Serfaty, Lawrence, Tony Andréani, H. Fontaine, et al.. (2000). Sequential treatment with lamivudine and interferon in patients with chronic hepatitis B non responder to interferon alone. Journal of Hepatology. 32. 103–103. 1 indexed citations
17.
Legendre, C., Valérie Garrigue, Christine Le Bihan-Benjamin, et al.. (1998). HARMFUL LONG-TERM IMPACT OF HEPATITIS C VIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation. 65(5). 667–670. 205 indexed citations
18.
Pialoux, Gilles, Françoise Carnot, Catherine Offredo, et al.. (1995). Value of Liver Biopsy for the Rapid Diagnosis of Infection in Human Immunodeficiency Virus-Infected Patients Who Have Unexplained Fever and Elevated Serum Levels of Alkaline Phosphatase or  -Glutamyl Transferase. Clinical Infectious Diseases. 20(3). 606–610. 18 indexed citations
19.
Pol, S., Claudine Saltiel, Claire Legendre, et al.. (1994). Effectiveness of adenine arabinoside 5'-monophosphate in kidney transplant recipients with chronic active hepatitis B. Nephrology Dialysis Transplantation. 9(7). 820–823. 5 indexed citations
20.
Debure, A., Henri Kreis, Claude Degott, et al.. (1990). Chronic hepatitis in kidney allograft recipients. The Lancet. 335(8694). 878–880. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Fretz Breakdown of academic impact, for papers by C. Cornù Breakdown of academic impact, for papers by P. Wantzin Breakdown of academic impact, for papers by Raymond T. Chung Breakdown of academic impact, for papers by H. Benalia Breakdown of academic impact, for papers by Roberto José de Carvalho‐Filho Breakdown of academic impact, for papers by Jeanne Serpaggi Breakdown of academic impact, for papers by Sergio Rojter Breakdown of academic impact, for papers by M. Abradelo Breakdown of academic impact, for papers by Sylvie Radenne
Rankless by CCL
2026